Table 2

Effects on restenosis of NCX-4016 versus aspirin in hypercholesterolemic LDL receptor-deficient mice

Injury scoreNeointimal area, μm2% Lumen stenosisNumber of neointimal cells% Proliferating cells, VSMC/PCNANeointimal cell density, n/0.1 mm2
Controls (n = 8; balloon injury)1.81  ± 0.1434.9  ± 1.872.9  ± 3.19399.9  ± 19.848.2  ± 2.0765  ± 82
Group 1 (n = 8; 10 mg/Kg NCX-4016 Protocol 1)1.83  ± 0.0818.8  ± 0.8*31.4  ± 2.32*223.3  ± 13.1*14.6  ± 0.5*436  ± 41*
Group 2 (n = 8; 30 mg/Kg NCX-4016 Protocol 1)1.82  ± 0.0916.4  ± 0.5*28.9  ± 1.45*200.4  ± 11.2*11.2  ± 0.3*406  ± 32*
Group 3 (n = 8; 16 mg/Kg Aspirin Protocol 1)1.89  ± 0.0923.8  ± 0.9*42.8  ± 3.12*298.9  ± 15.6*22.8  ± 0.6*545  ± 41*
Group 4 (n = 8; 54 mg/Kg Aspirin Protocol 1)1.84  ± 0.0621.2  ± 0.6*39.6  ± 2.83*272.8  ± 12.5*19.9  ± 0.5*508  ± 29*
Group 5 (n = 8; 10 mg/Kg NCX-4016 Protocol 2)1.86  ± 0.0822.8  ± 0.8*42.8  ± 2.64*284.3  ± 12.7*21.8  ± 0.5*521  ± 39*
Group 6 (n = 8; 30 mg/Kg NCX-4016 Protocol 2)1.89  ± 0.0920.9  ± 0.5*36.5  ± 3.11*252.1  ± 13.3*18.4  ± 0.4*488  ± 29*
Group 7 (n = 8; 16 mg/Kg Aspirin Protocol 2)1.86  ± 0.0732.8  ± 1.864.5  ± 4.95382.5  ± 17.145.5  ± 1.5679  ± 94
Group 8 (n = 8; 54 mg/Kg Aspirin Protocol 2)1.85  ± 0.0629.9  ± 2.661.5  ± 3.85**332.5  ± 14.6**31.9  ± 1.6*622  ± 78
  • Values are mean ± SE. Protocol 1: 7 days before and 21 days after injury treatment; Protocol 2: 21 days after injury treatment. 

  • * , P < 0.01 vs. controls; **, P < 0.05 vs. vehicle-controls;  

  • , P < 0.05 vs. respective aspirin dose in the same protocol;  

  • , P < 0.05 vs. respective treatment between protocols.